Risks and Benefits of Antiplatelet Therapy in Uremic Patients

被引：12
|
作者：
Washam, Jeffrey B.
Adams, George L. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Duke Heart Ctr, Durham, NC 27710 USA
来源：
ADVANCES IN CHRONIC KIDNEY DISEASE | 2008年 / 15卷 / 04期
关键词：
Uremia; Antiplatelet therapy; Acute coronary syndrome;
D O I：
10.1053/j.ackd.2008.07.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with renal insufficiency are at an increased risk for cardiovascular morbidity and mortality. Despite being at a substantial risk for thrombotic events, patients with renal insufficiency also experience a greater number of hemorrhagic complications associated with antiplatelet therapy than individuals with normal renal function. This review focuses on the benefits and risks of antiplatelet therapy in patients with impaired kidney function suffering from an acute coronary syndrome. (C) 2008 by the National Kidney Foundation, Inc. All rights reserved
引用
收藏
页码：370 / 377
页数：8
相关论文
共 50 条
  • [1] Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits?
    Asencio, Luis Alejandro
    Huang, Jennifer J.
    Alpert, Joseph S.
    AMERICAN JOURNAL OF MEDICINE, 2014, 127 (07) : 579 - 585
  • [2] Patient and Physician Perspectives on the Benefits and Risks of Antiplatelet Therapy for Acute Coronary Syndrome
    Cohen, Marc
    Jones, Colin
    CARDIOLOGY AND THERAPY, 2024, 13 (03) : 631 - 643
  • [3] Benefits and risks with antiplatelet therapy: how great a problem is bleeding?
    Husted, Steen
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2008, 10 (0I) : 19 - 24
  • [4] Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction
    Yeh, Robert W.
    Kereiakes, Dean J.
    Steg, Philippe Gabriel
    Windecker, Stephan
    Rinaldi, Michael J.
    Gershlick, Anthony H.
    Cutlip, Donald E.
    Cohen, David J.
    Tanguay, Jean-Francois
    Jacobs, Alice
    Wiviott, Stephen D.
    Massaro, Joseph M.
    Iancu, Adrian C.
    Mauri, Laura
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (20) : 2211 - 2221
  • [5] Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: A meta-analysis of cohort studies
    Ding, Xueying
    Liu, Xi
    Tan, Changhong
    Yin, Maojia
    Wang, Teng
    Liu, Ying
    Mo, Lijuan
    Wei, Xin
    Tan, Xinjie
    Deng, Fen
    Chen, Lifen
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 384 : 133 - 138
  • [6] Modern Antiplatelet Therapy - Opportunities and Risks
    Protasiewicz, Marcin
    Szymkiewicz, Pawel
    Kuliczkowski, Wiktor
    Mysiak, Andrzej
    Witkiewicz, Wojciech
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2013, 22 (06): : 875 - 885
  • [7] Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions
    N. Bennaghmouch
    W. J. M. Dewilde
    J. M. Ten Berg
    Current Cardiology Reports, 2014, 16
  • [8] Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions
    Bennaghmouch, N.
    Dewilde, W. J. M.
    Ten Berg, J. M.
    CURRENT CARDIOLOGY REPORTS, 2014, 16 (12)
  • [9] Selecting Antiplatelet Therapy at the Time of Percutaneous Intervention for an Acute Coronary Syndrome Weighing the Benefits and Risks of Prasugrel Versus Clopidogrel
    Salisbury, Adam C.
    Wang, Kaijun
    Cohen, David J.
    Li, Yan
    Jones, Philip G.
    Spertus, John A.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2013, 6 (01): : 27 - 34
  • [10] Double antiplatelet therapy in patients with acute coronary syndrome
    Rodionov, A. V.
    Aynetdinova, D. Kh.
    Sulimov, V. A.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2011, 10 (05): : 87 - 91
12345